345 E. Main St. |
|
Warsaw, IN 46580 |
|
www.zimmerbiomet.com | Exhibit 99.1 |
Media | Investors |
Meredith Weissman | Keri Mattox |
(703) 346-3127 | (215) 275-2431 |
meredith.weissman@zimmerbiomet.com | keri.mattox@zimmerbiomet.com |
|
|
| Ezgi Yagci |
| (617) 549-2443 |
| ezgi.yagci@zimmerbiomet.com |
Zimmer Biomet Announces Second Quarter 2022 Financial Results
(WARSAW, IN) August 2, 2022 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2022. The Company reported second quarter net sales from continuing operations of $1.782 billion, an increase of 1.0% over the prior year period, and an increase of 6.0% on a constant currency basis. Net earnings from continuing operations for the second quarter were $153.7 million, or $382.4 million on an adjusted1 basis.
Diluted earnings per share from continuing operations were $0.73 for the second quarter, and adjusted diluted earnings per share from continuing operations were $1.82.
Page 1 of 22
“Our performance in Q2 was well above our own internal expectations due to stronger than anticipated COVID recovery in the quarter and the continued execution from the ZB team across our regions and segments. Despite expected increased pressure from foreign exchange rates and inflation, we are once again updating our guidance,” said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. “We believe our focus on innovation and the transformation of our business continues to position us well for long-term growth and continued delivery for our shareholders.”
Recent Highlights
Aligned with the ongoing transformation of Zimmer Biomet's business, key second quarter highlights include:
Geographic and Product Category Sales
The following sales tables provide results by geography and product category for the three and six-month periods ended June 30, 2022, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis.
Page 2 of 22
NET SALES - THREE MONTHS ENDED JUNE 30, 2022 | |||||||||||||
(in millions, unaudited) |
|
| |||||||||||
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
| Constant |
|
| |||
| Net |
|
|
|
|
|
| Currency |
|
| |||
| Sales |
|
| % Change |
|
|
| % Change |
|
| |||
Geographic Results |
|
|
|
|
|
|
|
|
|
| |||
United States | $ | 1,017.6 |
|
|
| 1.3 |
| % |
|
| 1.3 |
| % |
International |
| 764.2 |
|
|
| 0.7 |
|
|
|
| 12.2 |
|
|
Total | $ | 1,781.8 |
|
|
| 1.0 |
| % |
|
| 6.0 |
| % |
Product Categories |
|
|
|
|
|
|
|
|
|
| |||
Knees |
|
|
|
|
|
|
|
|
|
| |||
United States | $ | 398.4 |
|
|
| 4.5 |
| % |
|
| 4.5 |
| % |
International |
| 306.5 |
|
|
| 7.8 |
|
|
|
| 20.1 |
|
|
Total |
| 704.9 |
|
|
| 5.9 |
|
|
|
| 11.2 |
|
|
Hips |
|
|
|
|
|
|
|
|
|
| |||
United States |
| 247.5 |
|
|
| 2.6 |
|
|
|
| 2.6 |
|
|
International |
| 239.7 |
|
|
| 2.8 |
|
|
|
| 14.9 |
|
|
Total |
| 487.2 |
|
|
| 2.7 |
|
|
|
| 8.6 |
|
|
S.E.T. * |
| 446.4 |
|
|
| (3.4 | ) |
|
|
| 0.1 |
|
|
Other |
| 143.3 |
|
|
| (11.0 | ) |
|
|
| (6.1 | ) |
|
Total | $ | 1,781.8 |
|
|
| 1.0 |
| % |
|
| 6.0 |
| % |
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
| |||
* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic |
|
|
NET SALES - SIX MONTHS ENDED JUNE 30, 2022 | ||||||||||||
(in millions, unaudited) | ||||||||||||
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| Constant |
|
| |||
| Net |
|
|
|
|
| Currency |
|
| |||
| Sales |
|
| % Change |
|
| % Change |
|
| |||
Geographic Results |
|
|
|
|
|
|
|
|
| |||
United States | $ | 1,958.8 |
|
|
| 3.5 |
| % |
| 3.5 |
| % |
International |
| 1,486.2 |
|
|
| 1.0 |
|
|
| 10.2 |
|
|
Total | $ | 3,445.0 |
|
|
| 2.4 |
| % |
| 6.4 |
| % |
Product Categories |
|
|
|
|
|
|
|
|
| |||
Knees |
|
|
|
|
|
|
|
|
| |||
United States | $ | 777.9 |
|
|
| 7.9 |
| % |
| 7.9 |
| % |
International |
| 589.8 |
|
|
| 5.5 |
|
|
| 15.1 |
|
|
Total |
| 1,367.7 |
|
|
| 6.9 |
|
|
| 11.1 |
|
|
Hips |
|
|
|
|
|
|
|
|
| |||
United States |
| 472.1 |
|
|
| 2.9 |
|
|
| 2.9 |
|
|
International |
| 466.1 |
|
|
| 0.7 |
|
|
| 10.3 |
|
|
Total |
| 938.2 |
|
|
| 1.8 |
|
|
| 6.6 |
|
|
S.E.T. * |
| 863.2 |
|
|
| (1.9 | ) |
|
| 1.0 |
|
|
Other |
| 275.9 |
|
|
| (2.7 | ) |
|
| 1.5 |
|
|
Total | $ | 3,445.0 |
|
|
| 2.4 |
| % |
| 6.4 |
| % |
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
| |||
* Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic |
|
|
|
Page 3 of 22
Financial Guidance
The Company is updating its full-year 2022 financial guidance to raise its previous projected ranges for revenue growth, foreign currency exchange impact, adjusted operating profit margin and adjusted diluted EPS from continuing operations:
Projected Year Ending December 31, 2022 | ||
| Previous Guidance | Updated Guidance |
2022 Reported Revenue Change | (1.5)% - 0.5% | (1.0)% - 1.0% |
Foreign Currency Exchange Impact | (3.5)% | (5.0)% |
Adjusted Operating Profit Margin(1) | 26.5% - 27.5% | 26.75% - 27.75% |
Adjusted Tax Rate(1) | 16.0% - 16.5% | 16.0% - 16.5% |
Adjusted Diluted EPS from Continuing Operations(1) | $6.65 - $6.85 | $6.70 - $6.90 |
(1) | These measures are non-GAAP financial measures for which a reconciliation to the most directly comparable GAAP financial measure is not available without unreasonable efforts. See “Forward-Looking Non-GAAP Financial Measures.” |
Conference Call
The Company will conduct its second quarter investor conference call today, August 2, 2022, at 8:30 a.m. ET. The audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be archived for replay following the conference call.
About the Company
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Page 4 of 22
Website Information
We routinely post important information for investors on our website, www.zimmerbiomet.com, in the “Investor Relations” section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts.
The information contained on, or that may be accessed through, our website or any other website referenced herein is not incorporated by reference into, and is not a part of, this document.
Note on Non-GAAP Financial Measures
This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.
Net sales from continuing operations change information for the three and six-month periods ended June 30, 2022 is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.
Net earnings from continuing operations and diluted earnings per share from continuing operations for the three and six-month periods ended June 30, 2022 and 2021 are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted earnings from continuing operations and adjusted diluted earnings per share from continuing operations exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.
Free cash flow from continuing operations is an additional non-GAAP measure that is presented in this press release. Free cash flow from continuing operations is computed by deducting additions to instruments and other property, plant and equipment of continuing operations from net cash provided by operating activities from continuing operations.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this press release. This press release also contains supplemental reconciliations of additional non-GAAP financial measures that the Company
Page 5 of 22
presents in other contexts. These additional non-GAAP financial measures are computed from the most directly comparable GAAP financial measure as indicated in the applicable reconciliation.
Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the Company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures. In addition, constant currency sales changes, adjusted operating profit, adjusted diluted earnings per share from continuing operations and free cash flow from continuing operations are used as performance metrics in our incentive compensation programs.
Forward-Looking Non-GAAP Financial Measures
This press release also includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2022. We calculate forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to initial compliance with the European Union Medical Device Regulation; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration, divestiture and related; certain legal and tax matters; and discontinued operations. We have not provided quantitative reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding financial guidance, the impact of the COVID-19 pandemic on our business, including any
Page 6 of 22
continued recovery, and any statements about our forecasts, expectations, plans, intentions, strategies or prospects. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: the effects of the COVID-19 global pandemic and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective surgical procedures and our ability to collect accounts receivable; the failure of vaccine rollouts and other strategies to mitigate or reverse the impacts of the COVID-19 pandemic; the emergence of new pandemic variants; the failure of elective surgical procedures to recover at the levels or on the timeline anticipated; the risks and uncertainties related to our ability to successfully execute our restructuring plans; our ability to attract, retain and develop the highly skilled employees we need to support our business; the success of our quality and operational excellence initiatives, including ongoing quality remediation efforts at our Warsaw North Campus facility; the ability to remediate matters identified in inspectional observations or warning letters issued by the U.S. Food and Drug Administration (FDA), while continuing to satisfy the demand for our products; the risks and uncertainties associated with the spinoff of ZimVie Inc. (ZimVie), including, without limitation, the tax-free nature of the transaction, the tax-efficient nature of any subsequent disposal of any ZimVie common stock we retain, possible disruptions in our relationships with customers, suppliers and other business partners and the possibility that the anticipated benefits and synergies of the transaction, strategic and competitive advantages, and future growth and other opportunities will not be realized within the expected time periods or at all; the impact of substantial indebtedness on our ability to service our debt obligations and/or refinance amounts outstanding under our debt obligations at maturity on terms favorable to us, or at all; the ability to retain the employees, independent agents and distributors who market our products; dependence on a limited number of suppliers for key raw materials and outsourced activities; the possibility that the anticipated synergies and other benefits from mergers and acquisitions will not be realized, or will not be realized within the expected time periods; the risks and uncertainties related to our ability to successfully integrate the operations, products, employees and distributors of acquired companies; the effect of the potential disruption of management’s attention from ongoing business operations due to integration matters related to mergers and acquisitions; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the FDA and foreign
Page 7 of 22
government regulators, such as more stringent requirements for regulatory clearance of products; the outcome of government and regulatory investigations; competition; pricing pressures; changes in customer demand for our products and services caused by demographic changes or other factors; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors and cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare purchasing organizations, including the volume-based procurement in China; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials, especially of titanium used in our products, and products; control of costs and expenses; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations; the domestic and international business impact of political, social and economic instability, tariffs, trade embargoes, sanctions, wars, disputes and other conflicts; the effects of inflation, including the effects of different rates of inflation in different countries, on our costs and the costs of our products; the effects of supply chain continuity disruptions; and the impact of the ongoing financial and political uncertainty on countries in EMEA relating to the Russian-Ukrainian crisis and otherwise, on the ability to collect accounts receivable in affected countries. A further list and description of these risks and uncertainties and other factors can be found in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and our subsequent filings with the Securities and Exchange Commission (SEC). Copies of these filings are available online at www.sec.gov, www.zimmerbiomet.com or on request from us. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in our filings with the SEC. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.
###
Page 8 of 22
|
| ||||||
ZIMMER BIOMET HOLDINGS, INC. |
| ||||||
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS |
| ||||||
FOR THE THREE MONTHS ENDED JUNE 30, 2022 and 2021 |
| ||||||
(in millions, except per share amounts, unaudited) |
| ||||||
|
|
|
|
|
| ||
| 2022 |
|
| 2021 |
| ||
Net Sales | $ | 1,781.8 |
|
| $ | 1,763.3 |
|
Cost of products sold, excluding intangible asset amortization |
| 511.0 |
|
|
| 496.2 |
|
Intangible asset amortization |
| 133.0 |
|
|
| 132.9 |
|
Research and development |
| 99.4 |
|
|
| 165.0 |
|
Selling, general and administrative |
| 695.2 |
|
|
| 696.8 |
|
Intangible asset impairment |
| 3.0 |
|
|
| 16.3 |
|
Restructuring and other cost reduction initiatives |
| 57.0 |
|
|
| 18.8 |
|
Quality remediation |
| 7.8 |
|
|
| 11.0 |
|
Acquisition, integration, divestiture and related |
| (5.5 | ) |
|
| 1.5 |
|
Operating expenses |
| 1,500.9 |
|
|
| 1,538.5 |
|
Operating Profit |
| 280.9 |
|
|
| 224.8 |
|
Other (expense) income, net |
| (42.6 | ) |
|
| 8.0 |
|
Interest expense, net |
| (38.8 | ) |
|
| (54.7 | ) |
Earnings from continuing operations before income taxes |
| 199.5 |
|
|
| 178.1 |
|
Provision for income taxes from continuing operations |
| 45.5 |
|
|
| 33.3 |
|
Net Earnings from continuing operations |
| 154.0 |
|
|
| 144.8 |
|
Less: Net earnings attributable to noncontrolling interest |
| 0.3 |
|
|
| 0.6 |
|
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
| 153.7 |
|
|
| 144.2 |
|
Loss from discontinued operations, net of taxes |
| - |
|
|
| (2.3 | ) |
Net Earnings of Zimmer Biomet Holdings, Inc. | $ | 153.7 |
|
| $ | 141.9 |
|
|
|
|
|
|
| ||
Earnings Per Common Share - Basic |
|
|
|
|
| ||
Earnings from continuing operations | $ | 0.73 |
|
| $ | 0.69 |
|
Loss from discontinued operations |
| - |
|
|
| (0.01 | ) |
Net Earnings Per Common Share - Basic | $ | 0.73 |
|
| $ | 0.68 |
|
Earnings Per Common Share - Diluted |
|
|
|
|
| ||
Earnings from continuing operations | $ | 0.73 |
|
| $ | 0.68 |
|
Loss from discontinued operations |
| - |
|
|
| (0.01 | ) |
Net Earnings Per Common Share - Diluted | $ | 0.73 |
|
| $ | 0.67 |
|
Weighted Average Common Shares Outstanding |
|
|
|
|
| ||
Basic |
| 209.6 |
|
|
| 208.6 |
|
Diluted |
| 210.3 |
|
|
| 210.7 |
|
|
|
|
|
|
| ||
|
| ||||||
|
|
Page 9 of 22
|
| ||||||
ZIMMER BIOMET HOLDINGS, INC. |
| ||||||
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS |
| ||||||
FOR THE SIX MONTHS ENDED JUNE 30, 2022 and 2021 |
| ||||||
(in millions, except per share amounts, unaudited) |
| ||||||
|
|
|
|
|
| ||
| 2022 |
|
| 2021 |
| ||
Net Sales | $ | 3,445.0 |
|
| $ | 3,364.7 |
|
Cost of products sold, excluding intangible asset amortization |
| 1,011.0 |
|
|
| 932.5 |
|
Intangible asset amortization |
| 263.8 |
|
|
| 266.5 |
|
Research and development |
| 196.3 |
|
|
| 246.0 |
|
Selling, general and administrative |
| 1,379.7 |
|
|
| 1,353.8 |
|
Intangible asset impairment |
| 3.0 |
|
|
| 16.3 |
|
Restructuring and other cost reduction initiatives |
| 100.9 |
|
|
| 40.1 |
|
Quality remediation |
| 14.3 |
|
|
| 21.1 |
|
Acquisition, integration, divestiture and related |
| (3.3 | ) |
|
| 4.9 |
|
Operating expenses |
| 2,965.7 |
|
|
| 2,881.2 |
|
Operating Profit |
| 479.3 |
|
|
| 483.5 |
|
Other (expense) income, net |
| (98.7 | ) |
|
| 15.7 |
|
Interest expense, net |
| (79.9 | ) |
|
| (107.0 | ) |
Earnings from continuing operations before income taxes |
| 300.7 |
|
|
| 392.2 |
|
Provision for income taxes from continuing operations |
| 73.5 |
|
|
| 54.4 |
|
Net Earnings from continuing operations |
| 227.2 |
|
|
| 337.8 |
|
Less: Net earnings attributable to noncontrolling interest |
| 0.5 |
|
|
| 0.2 |
|
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
| 226.7 |
|
|
| 337.6 |
|
(Loss) earnings from discontinued operations, net of taxes |
| (58.8 | ) |
|
| 2.4 |
|
Net Earnings of Zimmer Biomet Holdings, Inc. | $ | 167.9 |
|
| $ | 340.0 |
|
|
|
|
|
|
| ||
Earnings Per Common Share - Basic |
|
|
|
|
| ||
Earnings from continuing operations | $ | 1.08 |
|
| $ | 1.62 |
|
(Loss) earnings from discontinued operations |
| (0.28 | ) |
|
| 0.01 |
|
Net Earnings Per Common Share - Basic | $ | 0.80 |
|
| $ | 1.63 |
|
Earnings Per Common Share - Diluted |
|
|
|
|
| ||
Earnings from continuing operations | $ | 1.08 |
|
| $ | 1.60 |
|
(Loss) earnings from discontinued operations |
| (0.28 | ) |
|
| 0.01 |
|
Net Earnings Per Common Share - Diluted | $ | 0.80 |
|
| $ | 1.61 |
|
Weighted Average Common Shares Outstanding |
|
|
|
|
| ||
Basic |
| 209.4 |
|
|
| 208.3 |
|
Diluted |
| 210.2 |
|
|
| 210.4 |
|
|
|
|
|
|
| ||
|
| ||||||
|
|
Page 10 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
| |||||||
(in millions, unaudited) |
| |||||||
|
| |||||||
|
| June 30, |
|
| December 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
Assets |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 386.4 |
|
| $ | 378.1 |
|
Receivables, net |
|
| 1,282.1 |
|
|
| 1,259.6 |
|
Inventories |
|
| 2,122.7 |
|
|
| 2,148.0 |
|
Other current assets |
|
| 671.7 |
|
|
| 597.7 |
|
Current assets of discontinued operations |
|
| - |
|
|
| 501.6 |
|
Total current assets |
|
| 4,462.9 |
|
|
| 4,885.0 |
|
Property, plant and equipment, net |
|
| 1,796.6 |
|
|
| 1,836.6 |
|
Goodwill |
|
| 8,868.9 |
|
|
| 8,919.4 |
|
Intangible assets, net |
|
| 5,304.4 |
|
|
| 5,533.6 |
|
Other assets |
|
| 1,019.9 |
|
|
| 1,005.0 |
|
Noncurrent assets of discontinued operations |
|
| - |
|
|
| 1,276.8 |
|
Total Assets |
| $ | 21,452.7 |
|
| $ | 23,456.4 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
| ||
Current liabilities |
| $ | 1,611.7 |
|
| $ | 1,685.6 |
|
Current portion of long-term debt |
|
| 851.9 |
|
|
| 1,605.1 |
|
Current liabilities of discontinued operations |
|
| - |
|
|
| 177.2 |
|
Other long-term liabilities |
|
| 1,692.5 |
|
|
| 1,690.0 |
|
Long-term debt |
|
| 5,172.0 |
|
|
| 5,463.7 |
|
Noncurrent liabilities of discontinued operations |
|
| - |
|
|
| 168.4 |
|
Stockholders' equity |
|
| 12,124.6 |
|
|
| 12,666.4 |
|
Total Liabilities and Stockholders' Equity |
| $ | 21,452.7 |
|
| $ | 23,456.4 |
|
Page 11 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| |||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
| |||||||
FOR THE SIX MONTHS ENDED JUNE 30, 2022 and 2021 |
| |||||||
(in millions, unaudited) |
| |||||||
|
|
|
|
|
|
| ||
|
| 2022 |
|
| 2021 |
| ||
Cash flows provided by (used in) operating activities from continuing operations |
|
|
|
|
|
| ||
Net earnings from continuing operations |
| $ | 227.2 |
|
| $ | 337.8 |
|
Depreciation and amortization |
|
| 466.5 |
|
|
| 471.5 |
|
Share-based compensation |
|
| 50.8 |
|
|
| 42.4 |
|
Intangible asset impairment |
|
| 3.0 |
|
|
| 16.3 |
|
Changes in operating assets and liabilities, net of acquired assets and liabilities |
|
|
|
|
|
| ||
Income taxes |
|
| 13.0 |
|
|
| (28.1 | ) |
Receivables |
|
| (81.8 | ) |
|
| 0.6 |
|
Inventories |
|
| (26.4 | ) |
|
| (88.9 | ) |
Accounts payable and accrued liabilities |
|
| (49.9 | ) |
|
| (48.5 | ) |
Other assets and liabilities |
|
| 58.8 |
|
|
| (60.6 | ) |
Net cash provided by operating activities from continuing operations |
|
| 661.2 |
|
|
| 642.5 |
|
Cash flows provided by (used in) investing activities from continuing operations |
|
|
|
|
|
| ||
Additions to instruments |
|
| (120.6 | ) |
|
| (133.3 | ) |
Additions to other property, plant and equipment |
|
| (77.3 | ) |
|
| (50.4 | ) |
Net investment hedge settlements |
|
| 33.9 |
|
|
| (9.6 | ) |
Business combination investments, net of acquired cash |
|
| (99.8 | ) |
|
| - |
|
Investments in other assets |
|
| (60.5 | ) |
|
| (13.7 | ) |
Net cash used in investing activities from continuing operations |
|
| (324.3 | ) |
|
| (207.0 | ) |
Cash flows provided by (used in) financing activities from continuing operations |
|
|
|
|
|
| ||
Proceeds from revolving facility |
|
| 220.0 |
|
|
| - |
|
Payments on revolving facility |
|
| (220.0 | ) |
|
| - |
|
Redemption of senior notes |
|
| (750.0 | ) |
|
| (200.0 | ) |
Dividends paid to stockholders |
|
| (100.5 | ) |
|
| (99.8 | ) |
Proceeds from employee stock compensation plans |
|
| 45.0 |
|
|
| 91.5 |
|
Distribution from ZimVie, Inc. |
|
| 540.6 |
|
|
| - |
|
Business combination contingent consideration payments |
|
| - |
|
|
| (6.5 | ) |
Other financing activities |
|
| (3.5 | ) |
|
| (9.3 | ) |
Net cash used in financing activities from continuing operations |
|
| (268.4 | ) |
|
| (224.1 | ) |
Cash flows provided by (used in) discontinued operations |
|
|
|
|
|
| ||
Net cash (used in) provided by operating activities |
|
| (71.5 | ) |
|
| 57.9 |
|
Net cash used in investing activities |
|
| (7.2 | ) |
|
| (25.2 | ) |
Net cash used in financing activities |
|
| (68.1 | ) |
|
| - |
|
Net cash flows (used in) provided by discontinued operations |
|
| (146.8 | ) |
|
| 32.7 |
|
Effect of exchange rates on cash and cash equivalents |
|
| (13.8 | ) |
|
| (3.8 | ) |
(Decrease) increase in cash and cash equivalents |
|
| (92.1 | ) |
|
| 240.3 |
|
Cash and cash equivalents, beginning of period (includes $100.4 and $27.4 at January 1, 2022 and 2021, respectively, of discontinued operations cash) |
|
| 478.5 |
|
|
| 802.1 |
|
Cash and cash equivalents, end of period (includes $24.9 at June 30, 2021 of discontinued operations cash) |
| $ | 386.4 |
|
| $ | 1,042.4 |
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
Page 12 of 22
ZIMMER BIOMET HOLDINGS, INC. | ||||||||||||||
RECONCILIATION OF REPORTED NET SALES % CHANGE TO | ||||||||||||||
CONSTANT CURRENCY % CHANGE | ||||||||||||||
(unaudited) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
| |||
| For the Three Months Ended |
|
| |||||||||||
| June 30, 2022 vs. 2021 |
|
| |||||||||||
|
|
|
|
| Foreign |
|
|
| Constant |
|
| |||
|
|
|
|
| Exchange |
|
|
| Currency |
|
| |||
| % Change |
|
|
| Impact |
|
|
| % Change |
|
| |||
Geographic Results |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 1.3 |
| % |
|
| - |
| % |
|
| 1.3 |
| % |
International |
| 0.7 |
|
|
|
| (11.5 | ) |
|
|
| 12.2 |
|
|
Total |
| 1.0 |
| % |
|
| (5.0 | ) | % |
|
| 6.0 |
| % |
Product Categories |
|
|
|
|
|
|
|
|
|
|
| |||
Knees |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 4.5 |
| % |
|
| - |
| % |
|
| 4.5 |
| % |
International |
| 7.8 |
|
|
|
| (12.3 | ) |
|
|
| 20.1 |
|
|
Total |
| 5.9 |
|
|
|
| (5.3 | ) |
|
|
| 11.2 |
|
|
Hips |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 2.6 |
|
|
|
| - |
|
|
|
| 2.6 |
|
|
International |
| 2.8 |
|
|
|
| (12.1 | ) |
|
|
| 14.9 |
|
|
Total |
| 2.7 |
|
|
|
| (5.9 | ) |
|
|
| 8.6 |
|
|
S.E.T. |
| (3.4 | ) |
|
|
| (3.5 | ) |
|
|
| 0.1 |
|
|
Other |
| (11.0 | ) |
|
|
| (4.9 | ) |
|
|
| (6.1 | ) |
|
Total |
| 1.0 |
| % |
|
| (5.0 | ) | % |
|
| 6.0 |
| % |
Page 13 of 22
ZIMMER BIOMET HOLDINGS, INC. | ||||||||||||||
RECONCILIATION OF REPORTED NET SALES % CHANGE TO | ||||||||||||||
CONSTANT CURRENCY % CHANGE | ||||||||||||||
(unaudited) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
| |||
| For the Six Months Ended |
|
| |||||||||||
| June 30, 2022 vs. 2021 |
|
| |||||||||||
|
|
|
|
| Foreign |
|
|
| Constant |
|
| |||
|
|
|
|
| Exchange |
|
|
| Currency |
|
| |||
| % Change |
|
|
| Impact |
|
|
| % Change |
|
| |||
Geographic Results |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 3.5 |
| % |
|
| - |
| % |
|
| 3.5 |
| % |
International |
| 1.0 |
|
|
|
| (9.2 | ) |
|
|
| 10.2 |
|
|
Total |
| 2.4 |
| % |
|
| (4.0 | ) | % |
|
| 6.4 |
| % |
Product Categories |
|
|
|
|
|
|
|
|
|
|
| |||
Knees |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 7.9 |
| % |
|
| - |
| % |
|
| 7.9 |
| % |
International |
| 5.5 |
|
|
|
| (9.6 | ) |
|
|
| 15.1 |
|
|
Total |
| 6.9 |
|
|
|
| (4.2 | ) |
|
|
| 11.1 |
|
|
Hips |
|
|
|
|
|
|
|
|
|
|
| |||
United States |
| 2.9 |
|
|
|
| - |
|
|
|
| 2.9 |
|
|
International |
| 0.7 |
|
|
|
| (9.6 | ) |
|
|
| 10.3 |
|
|
Total |
| 1.8 |
|
|
|
| (4.8 | ) |
|
|
| 6.6 |
|
|
S.E.T |
| (1.9 | ) |
|
|
| (2.9 | ) |
|
|
| 1.0 |
|
|
Other |
| (2.7 | ) |
|
|
| (4.2 | ) |
|
|
| 1.5 |
|
|
Total |
| 2.4 |
| % |
|
| (4.0 | ) | % |
|
| 6.4 |
| % |
Page 14 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| |||||||||||||||||||||||||||||||||||||||||||||||
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS |
| |||||||||||||||||||||||||||||||||||||||||||||||
FOR THE THREE MONTHS ENDED JUNE, 2022 and 2021 |
| |||||||||||||||||||||||||||||||||||||||||||||||
(in millions, except per share amounts, unaudited) |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
FOR THE THREE MONTHS ENDED JUNE 30, 2022 |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| Cost of products sold, excluding intangible asset amortization |
|
| Intangible asset amortization |
|
| Research and development |
|
| Selling, general and administrative |
|
| Intangible asset impairment |
|
| Restructuring and other cost reduction initiatives |
|
| Quality remediation |
|
| Acquisition, integration, divestiture and related |
|
| Other (expense) income, net |
|
| Provision for income taxes from continuing operations |
|
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
|
| Diluted earnings from continuing operations per common share |
| ||||||||||||
As Reported |
| $ | 511.0 |
|
| $ | 133.0 |
|
| $ | 99.4 |
|
| $ | 695.2 |
|
| $ | 3.0 |
|
| $ | 57.0 |
|
| $ | 7.8 |
|
| $ | (5.5 | ) |
| $ | (42.6 | ) |
| $ | 45.5 |
|
| $ | 153.7 |
|
| $ | 0.73 |
|
Inventory and manufacturing-related charges(1) |
|
| (4.4 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3.7 |
|
|
| 0.7 |
|
|
| - |
|
Intangible asset amortization(2) |
|
| - |
|
|
| (133.0 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 26.7 |
|
|
| 106.3 |
|
|
| 0.51 |
|
Intangible asset impairment(3) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (3.0 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 0.8 |
|
|
| 2.2 |
|
|
| 0.01 |
|
Restructuring and other cost reduction initiatives(4) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (57.0 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 11.8 |
|
|
| 45.2 |
|
|
| 0.21 |
|
Quality remediation(5) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (7.8 | ) |
|
| - |
|
|
| - |
|
|
| 1.6 |
|
|
| 6.2 |
|
|
| 0.03 |
|
Acquisition, integration, divestiture and related(6) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 5.5 |
|
|
| - |
|
|
| 1.5 |
|
|
| (7.0 | ) |
|
| (0.03 | ) |
Litigation(7) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (3.5 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 1.1 |
|
|
| 2.4 |
|
|
| 0.01 |
|
European Union Medical Device Regulation(8) |
|
| - |
|
|
| - |
|
|
| (13.1 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3.0 |
|
|
| 10.1 |
|
|
| 0.05 |
|
Other charges(9) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1.0 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 41.7 |
|
|
| 1.1 |
|
|
| 41.6 |
|
|
| 0.20 |
|
Other certain tax adjustments(10) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (21.0 | ) |
|
| 21.0 |
|
|
| 0.10 |
|
As Adjusted |
| $ | 506.6 |
|
| $ | - |
|
| $ | 86.3 |
|
| $ | 690.7 |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | (0.9 | ) |
| $ | 75.8 |
|
| $ | 382.4 |
|
| $ | 1.82 |
|
FOR THE THREE MONTHS ENDED JUNE 30, 2021 |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| Cost of products sold, excluding intangible asset amortization |
|
| Intangible asset amortization |
|
| Research and development |
|
| Selling, general and administrative |
|
| Intangible asset impairment |
|
| Restructuring and other cost reduction initiatives |
|
| Quality remediation |
|
| Acquisition, integration, divestiture and related |
|
| Other (expense) income, net |
|
| Provision for income taxes from continuing operations |
|
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
|
| Diluted earnings from continuing operations per common share |
| ||||||||||||
As Reported |
| $ | 496.2 |
|
| $ | 132.9 |
|
| $ | 165.0 |
|
| $ | 696.8 |
|
| $ | 16.3 |
|
| $ | 18.8 |
|
| $ | 11.0 |
|
| $ | 1.5 |
|
| $ | 8.0 |
|
| $ | 33.3 |
|
| $ | 144.2 |
|
| $ | 0.68 |
|
Inventory and manufacturing-related charges(1) |
|
| (7.1 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 4.4 |
|
|
| 2.7 |
|
|
| 0.01 |
|
Intangible asset amortization(2) |
|
| - |
|
|
| (132.9 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 27.0 |
|
|
| 105.9 |
|
|
| 0.50 |
|
Intangible asset impairment(3) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (16.3 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 2.1 |
|
|
| 14.2 |
|
|
| 0.07 |
|
Restructuring and other cost reduction initiatives(4) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (18.8 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3.5 |
|
|
| 15.3 |
|
|
| 0.07 |
|
Quality remediation(5) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (11.0 | ) |
|
| - |
|
|
| - |
|
|
| 2.6 |
|
|
| 8.4 |
|
|
| 0.04 |
|
Acquisition, integration, divestiture and related(6) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1.5 | ) |
|
| - |
|
|
| 0.1 |
|
|
| 1.4 |
|
|
| 0.01 |
|
Litigation(7) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (3.6 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 0.4 |
|
|
| 3.2 |
|
|
| 0.02 |
|
European Union Medical Device Regulation(8) |
|
| - |
|
|
| - |
|
|
| (9.6 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 2.2 |
|
|
| 7.4 |
|
|
| 0.04 |
|
Other charges(9) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 1.5 |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (3.1 | ) |
|
| (3.0 | ) |
|
| (1.6 | ) |
|
| (0.01 | ) |
Other certain tax adjustments(10) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (17.0 | ) |
|
| 17.0 |
|
|
| 0.08 |
|
As Adjusted |
| $ | 489.1 |
|
| $ | - |
|
| $ | 155.4 |
|
| $ | 694.7 |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | 4.9 |
|
| $ | 55.6 |
|
| $ | 318.1 |
|
| $ | 1.51 |
|
Page 15 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| |||||||||||||||||||||||||||||||||||||||||||||||
RECONCILIATION OF REPORTED TO ADJUSTED RESULTS |
| |||||||||||||||||||||||||||||||||||||||||||||||
FOR THE SIX MONTHS ENDED JUNE 30, 2022 and 2021 |
| |||||||||||||||||||||||||||||||||||||||||||||||
(in millions, except per share amounts, unaudited) |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
FOR THE SIX MONTHS ENDED JUNE 30, 2022 |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| Cost of products sold, excluding intangible asset amortization |
|
| Intangible asset amortization |
|
| Research and development |
|
| Selling, general and administrative |
|
| Intangible asset impairment |
|
| Restructuring and other cost reduction initiatives |
|
| Quality remediation |
|
| Acquisition, integration, divestiture and related |
|
| Other (expense) income, net |
|
| Provision for income taxes from continuing operations |
|
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
|
| Diluted earnings from continuing operations per common share |
| ||||||||||||
As Reported |
| $ | 1,011.0 |
|
| $ | 263.8 |
|
| $ | 196.3 |
|
| $ | 1,379.7 |
|
| $ | 3.0 |
|
| $ | 100.9 |
|
| $ | 14.3 |
|
| $ | (3.3 | ) |
| $ | (98.7 | ) |
| $ | 73.5 |
|
| $ | 226.7 |
|
| $ | 1.08 |
|
Inventory and manufacturing-related charges(1) |
|
| (15.3 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 11.3 |
|
|
| 4.0 |
|
|
| 0.02 |
|
Intangible asset amortization(2) |
|
| - |
|
|
| (263.8 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 52.6 |
|
|
| 211.2 |
|
|
| 1.00 |
|
Intangible asset impairment(3) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (3.0 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 0.8 |
|
|
| 2.2 |
|
|
| 0.01 |
|
Restructuring and other cost reduction initiatives(4) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (100.9 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 18.2 |
|
|
| 82.7 |
|
|
| 0.39 |
|
Quality remediation(5) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (14.3 | ) |
|
| - |
|
|
| - |
|
|
| 3.1 |
|
|
| 11.2 |
|
|
| 0.05 |
|
Acquisition, integration, divestiture and related(6) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3.3 |
|
|
| - |
|
|
| 4.5 |
|
|
| (7.8 | ) |
|
| (0.04 | ) |
Litigation(7) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (35.1 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 8.0 |
|
|
| 27.1 |
|
|
| 0.13 |
|
European Union Medical Device Regulation(8) |
|
| - |
|
|
| - |
|
|
| (23.8 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 5.3 |
|
|
| 18.5 |
|
|
| 0.09 |
|
Other charges(9) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (5.2 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 102.2 |
|
|
| 2.5 |
|
|
| 104.9 |
|
|
| 0.50 |
|
Other certain tax adjustments(10) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (39.1 | ) |
|
| 39.1 |
|
|
| 0.19 |
|
As Adjusted |
| $ | 995.7 |
|
| $ | - |
|
| $ | 172.5 |
|
| $ | 1,339.4 |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | 3.5 |
|
| $ | 140.7 |
|
| $ | 719.8 |
|
| $ | 3.42 |
|
FOR THE SIX MONTHS ENDED JUNE 30, 2021 |
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| Cost of products sold, excluding intangible asset amortization |
|
| Intangible asset amortization |
|
| Research and development |
|
| Selling, general and administrative |
|
| Intangible asset impairment |
|
| Restructuring and other cost reduction initiatives |
|
| Quality remediation |
|
| Acquisition, integration, divestiture and related |
|
| Other (expense) income, net |
|
| Provision for income taxes from continuing operations |
|
| Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc. |
|
| Diluted earnings from continuing operations per common share |
| ||||||||||||
As Reported |
| $ | 932.5 |
|
| $ | 266.5 |
|
| $ | 246.0 |
|
| $ | 1,353.8 |
|
| $ | 16.3 |
|
| $ | 40.1 |
|
| $ | 21.1 |
|
| $ | 4.9 |
|
| $ | 15.7 |
|
| $ | 54.4 |
|
| $ | 337.6 |
|
| $ | 1.60 |
|
Inventory and manufacturing-related charges(1) |
|
| (1.2 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 9.8 |
|
|
| (8.6 | ) |
|
| (0.04 | ) |
Intangible asset amortization(2) |
|
| - |
|
|
| (266.5 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 54.4 |
|
|
| 212.1 |
|
|
| 1.01 |
|
Intangible asset impairment(3) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (16.3 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 2.1 |
|
|
| 14.2 |
|
|
| 0.07 |
|
Restructuring and other cost reduction initiatives(4) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (40.1 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 8.5 |
|
|
| 31.6 |
|
|
| 0.15 |
|
Quality remediation(5) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (21.1 | ) |
|
| - |
|
|
| - |
|
|
| 4.9 |
|
|
| 16.2 |
|
|
| 0.08 |
|
Acquisition, integration, divestiture and related(6) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (4.9 | ) |
|
| - |
|
|
| 1.8 |
|
|
| 3.1 |
|
|
| 0.01 |
|
Litigation(7) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (9.7 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 1.0 |
|
|
| 8.7 |
|
|
| 0.04 |
|
European Union Medical Device Regulation(8) |
|
| - |
|
|
| - |
|
|
| (16.1 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| 3.6 |
|
|
| 12.5 |
|
|
| 0.06 |
|
Other charges(9) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1.4 | ) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (7.2 | ) |
|
| (4.5 | ) |
|
| (1.3 | ) |
|
| (0.01 | ) |
Other certain tax adjustments(10) |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (18.5 | ) |
|
| 18.5 |
|
|
| 0.09 |
|
As Adjusted |
| $ | 931.3 |
|
| $ | - |
|
| $ | 229.9 |
|
| $ | 1,342.7 |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | - |
|
| $ | 8.5 |
|
| $ | 117.5 |
|
| $ | 644.6 |
|
| $ | 3.06 |
|
Page 16 of 22
Page 17 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| ||||||||||||||
RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES FROM |
| ||||||||||||||
CONTINUING OPERATIONS TO FREE CASH FLOW FROM CONTINUING OPERATIONS |
| ||||||||||||||
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 and 2021 |
| ||||||||||||||
(in millions, unaudited) |
| ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
| ||||||||||
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Net cash provided by operating activities from continuing operations | $ | 345.5 |
|
| $ | 419.0 |
|
| $ | 661.2 |
|
| $ | 642.5 |
|
Additions to instruments |
| (64.2 | ) |
|
| (61.1 | ) |
|
| (120.6 | ) |
|
| (133.3 | ) |
Additions to other property, plant and equipment |
| (40.9 | ) |
|
| (24.6 | ) |
|
| (77.3 | ) |
|
| (50.4 | ) |
Free cash flow from continuing operations | $ | 240.4 |
|
| $ | 333.3 |
|
| $ | 463.3 |
|
| $ | 458.8 |
|
Page 18 of 22
ZIMMER BIOMET HOLDINGS, INC. | ||||||||||||||||
RECONCILIATION OF GROSS PROFIT & MARGIN FROM CONTINUING OPERATIONS | ||||||||||||||||
TO ADJUSTED GROSS PROFIT & MARGIN FROM CONTINUING OPERATIONS | ||||||||||||||||
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 and 2021 | ||||||||||||||||
(in millions, unaudited) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
|
| ||||||||||
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
|
| ||||
Net Sales | $ | 1,781.8 |
|
| $ | 1,763.3 |
|
| $ | 3,445.0 |
|
| $ | 3,364.7 |
|
|
Cost of products sold, excluding intangible asset amortization |
| 511.0 |
|
|
| 496.2 |
|
|
| 1,011.0 |
|
|
| 932.5 |
|
|
Intangible asset amortization |
| 133.0 |
|
|
| 132.9 |
|
|
| 263.8 |
|
|
| 266.5 |
|
|
Gross Profit | $ | 1,137.8 |
|
| $ | 1,134.2 |
|
| $ | 2,170.2 |
|
| $ | 2,165.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Inventory and manufacturing-related charges |
| 4.4 |
|
|
| 7.1 |
|
|
| 15.3 |
|
|
| 1.2 |
|
|
Intangible asset amortization |
| 133.0 |
|
|
| 132.9 |
|
|
| 263.8 |
|
|
| 266.5 |
|
|
Adjusted gross profit | $ | 1,275.2 |
|
| $ | 1,274.2 |
|
| $ | 2,449.3 |
|
| $ | 2,433.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gross margin |
| 63.9 |
| % |
| 64.3 |
| % |
| 63.0 |
| % |
| 64.4 |
| % |
Inventory and manufacturing-related charges |
| 0.2 |
|
|
| 0.5 |
|
|
| 0.4 |
|
|
| - |
|
|
Intangible asset amortization |
| 7.5 |
|
|
| 7.5 |
|
|
| 7.7 |
|
|
| 7.9 |
|
|
Adjusted gross margin |
| 71.6 |
| % |
| 72.3 |
| % |
| 71.1 |
| % |
| 72.3 |
| % |
Page 19 of 22
ZIMMER BIOMET HOLDINGS, INC. | ||||||||||||||||
RECONCILIATION OF OPERATING PROFIT & MARGIN FROM CONTINUING OPERATIONS TO ADJUSTED OPERATING PROFIT & MARGIN FROM CONTINUING OPERATIONS | ||||||||||||||||
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 and 2021 | ||||||||||||||||
(in millions, unaudited) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended June 30, |
|
| Six Months Ended June 30, |
|
| ||||||||||
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
|
| ||||
Operating profit | $ | 280.9 |
|
| $ | 224.8 |
|
| $ | 479.3 |
|
| $ | 483.5 |
|
|
Inventory and manufacturing-related charges |
| 4.4 |
|
|
| 7.1 |
|
|
| 15.3 |
|
|
| 1.2 |
|
|
Intangible asset amortization |
| 133.0 |
|
|
| 132.9 |
|
|
| 263.8 |
|
|
| 266.5 |
|
|
Intangible asset impairment |
| 3.0 |
|
|
| 16.3 |
|
|
| 3.0 |
|
|
| 16.3 |
|
|
Restructuring and other cost reduction initiatives |
| 57.0 |
|
|
| 18.8 |
|
|
| 100.9 |
|
|
| 40.1 |
|
|
Quality remediation |
| 7.8 |
|
|
| 11.0 |
|
|
| 14.3 |
|
|
| 21.1 |
|
|
Acquisition, integration, divestiture and related |
| (5.5 | ) |
|
| 1.5 |
|
|
| (3.3 | ) |
|
| 4.9 |
|
|
Litigation |
| 3.5 |
|
|
| 3.6 |
|
|
| 35.1 |
|
|
| 9.7 |
|
|
European Union Medical Device Regulation |
| 13.1 |
|
|
| 9.6 |
|
|
| 23.8 |
|
|
| 16.1 |
|
|
Other charges |
| 1.0 |
|
|
| (1.5 | ) |
|
| 5.2 |
|
|
| 1.4 |
|
|
Adjusted operating profit | $ | 498.2 |
|
| $ | 424.1 |
|
| $ | 937.4 |
|
| $ | 860.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Operating profit margin |
| 15.8 |
| % |
| 12.7 |
| % |
| 13.9 |
| % |
| 14.4 |
| % |
Inventory and manufacturing-related charges |
| 0.2 |
|
|
| 0.5 |
|
|
| 0.4 |
|
|
| - |
|
|
Intangible asset amortization |
| 7.5 |
|
|
| 7.5 |
|
|
| 7.7 |
|
|
| 7.9 |
|
|
Intangible asset impairment |
| 0.2 |
|
|
| 0.9 |
|
|
| 0.1 |
|
|
| 0.5 |
|
|
Restructuring and other cost reduction initiatives |
| 3.2 |
|
|
| 1.1 |
|
|
| 2.9 |
|
|
| 1.2 |
|
|
Quality remediation |
| 0.4 |
|
|
| 0.6 |
|
|
| 0.4 |
|
|
| 0.6 |
|
|
Acquisition, integration, divestiture and related |
| (0.3 | ) |
|
| 0.1 |
|
|
| (0.1 | ) |
|
| 0.1 |
|
|
Litigation |
| 0.2 |
|
|
| 0.2 |
|
|
| 1.0 |
|
|
| 0.3 |
|
|
European Union Medical Device Regulation |
| 0.7 |
|
|
| 0.5 |
|
|
| 0.7 |
|
|
| 0.5 |
|
|
Other charges |
| 0.1 |
|
|
| (0.1 | ) |
|
| 0.2 |
|
|
| 0.1 |
|
|
Adjusted operating profit margin |
| 28.0 |
| % |
| 24.0 |
| % |
| 27.2 |
| % |
| 25.6 |
| % |
Page 20 of 22
ZIMMER BIOMET HOLDINGS, INC. | |||||||||||||||||
RECONCILIATION OF EFFECTIVE TAX RATE FROM CONTINUING OPERATIONS TO ADJUSTED EFFECTIVE TAX RATE FROM CONTINUING OPERATIONS | |||||||||||||||||
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 and 2021 | |||||||||||||||||
(unaudited) | |||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended June 30, |
|
|
| Six Months Ended June 30, |
|
| ||||||||||
| 2022 |
|
| 2021 |
|
|
| 2022 |
|
| 2021 |
|
| ||||
Effective tax rate |
| 22.8 |
| % |
| 18.7 |
| % |
|
| 24.5 |
| % |
| 13.9 |
| % |
Tax effect of adjustments made to earnings before taxes(1) |
| 4.2 |
|
|
| 5.7 |
|
|
|
| 4.7 |
|
|
| 6.2 |
|
|
Other certain tax adjustments |
| (10.5 | ) |
|
| (9.5 | ) |
|
|
| (12.9 | ) |
|
| (4.7 | ) |
|
Adjusted effective tax rate |
| 16.5 |
| % |
| 14.9 |
| % |
|
| 16.3 |
| % |
| 15.4 |
| % |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
(1) Includes inventory and manufacturing-related charges; intangible asset amortization; intangible asset impairment; restructuring and other cost reduction initiatives; quality remediation; acquisition, integration, divestiture and related; litigation; European Union Medical Device Regulation; and other charges |
Page 21 of 22
ZIMMER BIOMET HOLDINGS, INC. |
| ||||||
RECONCILIATION OF DEBT TO NET DEBT |
| ||||||
AS OF JUNE 30, 2022 and DECEMBER 31, 2021 |
| ||||||
(in millions, unaudited) |
| ||||||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
| June 30, 2022 |
|
| December 31, 2021 |
| ||
Debt, both current and long-term | $ | 6,023.9 |
|
| $ | 7,068.8 |
|
Cash and cash equivalents |
| (386.4 | ) |
|
| (378.1 | ) |
Net debt | $ | 5,637.5 |
|
| $ | 6,690.7 |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
Page 22 of 22